Komen group backs off Avastin for now; Pharma's Egypt offices step up security;

 @FiercePharma: GSK, Merck post Q4 losses on legal, R&D charges. News  | Follow @FiercePharma

> The Susan G. Komen for the Cure organization, one of the largest breast cancer advocacy groups, isn't promoting the use of Roche's Avastin for women who haven't previously taken it in the wake of questions about the drug's efficacy in advanced breast cancer. Report

> Staffers have been sent home and security has been bolstered at pharma offices located in Egypt's capital city amid protests in Tahrir Square that have turned violent in recent days. Article

> Valeant Pharmaceuticals sold $650 million of senior unsecured notes in the private placement market to help finance recent purchases. Story

> GlaxoSmithKline is hoping to pick up some talented scientists in its own backyard as Pfizer prepares to shutter its research center at Sandwich, southern England. News

> Concerned about the influence advertising may have on physicians, an Australian medical journal will no longer accept paid ads about prescription drugs and has called on other journals to take the same stand. Report

> India's Sun Pharmaceutical Industries said it won FDA approval to sell a generic version of the Alzheimer's disease drug Razadyne. Story

> CVS Caremark posted a decline in profit and revenue as its pharmacy-benefits business, acquired when CVS merged with Caremark nearly four years ago, continued to drag on results. Article

Biotech News

@FierceBiotech: Departing Pfizer researchers will get shriveled severance checks. Item | Follow @FierceBiotech

@JohnCFierce: Upbeat DSC127 data spurs spike in Derma shares. News  | Follow @JohnCFierce

> Marina, Debiopharm partner on RNAi-based bladder cancer work. News

> Bayer's regorafenib gets orphan drug designation. Report

> GSK's Witty: We're committed to Britain. Article

> Galapagos looks for new partner after Merck exits. Item

> Hedge fund: Actelion should explore sale. News

And Finally...  "Fat cancers" usually associated with wealthy countries are becoming more common in the developing world, too, according to new reports. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.